Our Science

ENABLING TECHNOLOGIES
ADDRESSING UNMET MEDICAL NEEDS

Our most advanced program, Neihulizumab, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.

Therapeutic Platform

Neihulizumab (AbGn-168H): Agonistic antibody with a unique mechanism of action—regulation of T cell homeostasis

Our lead inflammation drug candidate, Neihulizumab (AbGn-168H) is an immune checkpoint agonist antibody targeting PSGL-1/CD162 that regulates T cell homeostasis. This compound triggers a natural regulatory mechanism of T cell homeostasis in late stage activated T cells without affecting normal immune defenses. It has demonstrated proof-of-concept clinical efficacy in psoriasis as well as psoriatic arthritis, both of which are established T cell mediated diseases, and is currently being studied for the treatment of ulcerative colitis (phase II) and steroid refractory-acute GvHD (phase I).

Neihulizumab’s (AbGn-168H) unique mechanism of action provides a natural regulation of T cell homeostasis that induces cell death preferentially in late-stage activated T cells without affecting resting T cells and early-activated T cells. Because pathogenic T cells underlying the inflammatory conditions are usually in late-stage (chronically) activated state, eliminating this population of cells can potentially result in controlling autoimmune inflammation of T cell associated diseases, such as psoriasis, psoriatic arthritis, ulcerative colitis, multiple sclerosis, Type 1 diabetes and GvHD. Treatment with AbGn-168H could result in durable and long-term responses as the therapy is designed to eliminate the pathogenic T cells underlying these inflammatory conditions rather than simply inhibit them. In addition, since resting T cells are not affected, normal immune defenses are not impacted.

Close
more

Neihulizumab (AbGn-168H): Clinical-Stage Platform in Immunology

Neihulizumab (AbGn-168H) has demonstrated signs of clinical efficacy in Psoriasis and Psoriatic Arthritis, both of which are T-cell mediated diseases, and is being studied for the treatment of Ulcerative Colitis (phase II, NCT03298022) and steroid refractory-acute GvHD (phase I, NCT03327857).

Close
more

Close
more




Close
more

Close
more

Publications

Evaluation, Validation and Dissemination of ideas.

more

Patents

We are committed to responsible intellectual property management, creating a strong foundation for innovation.

In an effort to protect and expand our intellectual property portfolio, AltruBio actively pursues domestic and international patents for any commercially valuable inventions.